Novartis (NVS) Benefits From New Drugs & Key Acquisitions

Shares of Novartis AG NVS have gained 14.1% in the past six months compared with the industry’s growth of 10.3%. The company’s efforts to turnaround its business in 2018 has been impressive, given the loss of exclusivity for key drugs. The company made acquisitions to develop its pipeline in other promising areas. Novartis restructured its business in 2018 and plans to focus on becoming a core drug-focused company, powered by data and digital technologies.